Business
Karyopharm Announces Selinexor Data to be Presented at the 2022 American Society of Clinical Oncology Annual Meeting
NEWTON, Mass., April 27, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"NEWTON, Mass., April 27, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that four abstracts highlighting selinexor clinical research have been selected for presentation, including one oral presentation, at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7, 2022, in Chicago.\nResearch findings to be presented include an oral presentation discussing subgroup analyses and molecular classification data from the Phase 3 SIENDO study evaluating selinexor in endometrial cancer and a poster presentation highlighting preliminary results from a Phase 1/2 study evaluating selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis.\n\"At Karyopharm, we are laser focused on targeting cancers with high unmet need where our science enables us to make the biggest difference in the lives of patients,\" said Reshma Rangwala, MD, PhD, Chief Medical Officer of Karyopharm. \"We are excited to share the latest research at the 2022 ASCO Annual Meeting as these data underscore the innovation across our four core programs in clinical development.\"\nDetails for the 2022 ASCO Annual Meeting presentations are as follows:\nOral Presentation\nTitle: Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT - EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classificationPresenter: Vicky Makker, Memorial Sloan Kettering Cancer CenterAbstract #: 5511Date and time: Tuesday, June 7, 2022, 8:00 a.m. – 9:30 a.m. CDTSession: Clinical Science Symposium/Molecular-Based Treatment for Endometrial Cancer\nPoster PresentationsTitle: A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosisPresenter: Haris Ali, City of HopeAbstract #: 7060Date and time: Saturday, June 4, 2022, 8:00 a.m. – 11:00 a.m. CDTSession: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant\nTitle: Phase 1b study of weekly split-dose selinexor in soft tissue sarcoma (STS)Presenter: Abdulazeez Salawu, University Health NetworkAbstract #: 11563Date and time: Sunday, June 5, 2022, 8:00 a.m. – 11:00 a.m. CDTSession: Sarcoma\nTitle: Digital monitoring and assessments in pat...